332063-87-3
332063-87-3
Chemical Structure
SW157765
- CAS. Nr.: 332063-87-3
- Formula:C19H13N3O3
- Molecular Weight:331.32
IUPAC Name: (E)-3-(furan-2-yl)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-yl)acrylamide
InChIKey: QSSYRORXXFTVFI-GQCTYLIASA-N
SMILES: O=C(NC1=CC=C(OC(C2=CC=NC=C2)=N3)C3=C1)/C=C/C4=CC=CO4
Biological Activity: SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SW157765 | 98.08% | SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pine SR, et al. Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. Transl Lung Cancer Res. 2018;7(Suppl 3):S265-S269. [Content Brief]
- [2]. McMillan EA, et al. Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell. 2018;173(4):864-878.e29. [Content Brief]
